Molecular Biomarkers in Sinonasal Cancers: New Frontiers in Diagnosis and Treatment

Abstract

Purpose of Review Sinonasal tumors are rare and heterogeneous diseases which pose challenges in diagnosis and treatment. Despite significant progress made in surgical, oncological, and radiotherapy fields, their prognosis still remains poor. Therefore, alternative strategies should be studied in order to refine diagnosis and improve patient care. Recent Findings In recent years, in-depth molecular studies have identified new biological markers, such as genetic abnormalities and epigenetic variations, which have allowed to refine diagnosis and predict prognosis. As a consequence, new histological entities have been described and specific subgroup stratifications within the well-known histotypes have been made possible. These discoveries have expanded indications for immunotherapy and targeted therapies in order to reduce tumor spread, thus representing a valuable implementation of standard treatments. Summary Recent findings in molecular biology have paved the way for better understanding and managing such rare and aggressive tumors. Although further efforts need to be made in this direction, expectations are promising.

Olfactory dysfunction in patients with multiple sclerosis; A systematic review and meta-analysis

“…Inflammation seems like the pivotal concept that bridges CND inflammatory diseases and COVID-19 with olfactory dysfunction, since in both cases the NF-κB pathway signaling seems to play a crucial role [ 30 ]. There is accumulating evidence on the role of this signaling pathway in exacerbated inflammation, the development of MS, MS-related sensory-neural disturbances, and COVID-19-driven olfactory dysfunction [ 49 – 51 ]. Overall, not only do the findings demonstrate that screening for olfactory dysfunction can help diagnose susceptible individuals sooner, but it is also of potential benefit to predict MS patients’ disease progression.…”

Ligation of the ethmoid arteries in superselective intra‐arterial infusion of cisplatin for advanced maxillary sinus cancer fed by the ophthalmic artery

“…Gene expression analysis is utilized to develop and clinically use innovative treatment agents, such as targeted therapies and immune checkpoint inhibitors, and to uncover prognostic markers in head and neck cancer. 17,18 Precision medicine with molecularly targeted drugs and immune checkpoint inhibitors is also expected in advanced nasal sinus cancer.…”

Patterns of recurrences in sinonasal cancers undergoing an endoscopic surgery-based treatment: Results of the MUSES* on 940 patients

“…However, due to the high percentage of patients suffering from diffuse systemic localization of disease (28/38, 73.6% of the cases), the role of SOR was not significantly associated with survival in multivariable analysis, as opposed to TTR which showed association with SAR, with an HR of 0.971 (IC 0.945-0.996, p = 0.026). Altogether, with the very high rate and early onset of systemic failures, further research into immunotherapies and targeted therapies is urgently needed to improve on standard of care [49]. * For multivariable analysis of the variable SOR, distant recurrence (M) vs locoregional recurrence (T-N) was tested.…”